← All trials
NCT05216601
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 6, 2022
- Primary completion
- Jul 26, 2022
- Completion date
- Jan 31, 2023
- First posted
- Jan 31, 2022
- Last posted
- Sep 7, 2022
- Enrollment
- 120
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medigen Biotechnology CorporationLead sponsor
- Medigen Biotechnology CorporationStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.